These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 20851868)

  • 1. Viral encephalitis after allogeneic stem cell transplantation: a rare complication with distinct characteristics of different causative agents.
    Schmidt-Hieber M; Schwender J; Heinz WJ; Zabelina T; Kühl JS; Mousset S; Schüttrumpf S; Junghanss C; Silling G; Basara N; Neuburger S; Thiel E; Blau IW
    Haematologica; 2011 Jan; 96(1):142-9. PubMed ID: 20851868
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human herpesvirus-6 encephalitis following allogeneic hematopoietic stem cell transplantation.
    Vu T; Carrum G; Hutton G; Heslop HE; Brenner MK; Kamble R
    Bone Marrow Transplant; 2007 Jun; 39(11):705-9. PubMed ID: 17401392
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reconstitution of the Epstein-Barr virus-specific cytotoxic T-lymphocyte response following T-cell-depleted myeloablative and nonmyeloablative allogeneic stem cell transplantation.
    Chakrabarti S; Milligan DW; Pillay D; Mackinnon S; Holder K; Kaur N; McDonald D; Fegan CD; Waldmann H; Hale G; Rickinson A; Steven N
    Blood; 2003 Aug; 102(3):839-42. PubMed ID: 12869487
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human herpesvirus 6 encephalitis in patients administered mycophenolate mofetil as prophylaxis for graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
    Inui Y; Yakushijin K; Okamura A; Tanaka Y; Shinzato I; Nomura T; Ichikawa H; Mizutani Y; Kitao A; Kurata K; Kakiuchi S; Miyata Y; Sanada Y; Kitagawa K; Uryu K; Kawamoto S; Yamamoto K; Matsuoka H; Murayama T; Ito M; Minami H
    Transpl Infect Dis; 2019 Feb; 21(1):e13024. PubMed ID: 30414316
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low-dose alemtuzumab vs. standard policy for prevention of graft-versus-host disease in unrelated and related allogeneic stem cell transplantation-a matched pair analysis.
    Busemann C; Neumann T; Schulze M; Klenner A; Thiele T; Greinacher A; Dölken G; Krüger WH
    Ann Hematol; 2013 Jul; 92(7):945-52. PubMed ID: 23463451
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Are the Polyomaviruses BK and JC Associated with Opportunistic Infections, Graft-versus-Host Disease, or Worse Outcomes in Adult Patients Receiving Their First Allogeneic Stem Cell Transplantation with Low-Dose Alemtuzumab?
    Schneidewind L; Neumann T; Knoll F; Zimmermann K; Smola S; Schmidt CA; Krüger W
    Acta Haematol; 2017; 138(1):3-9. PubMed ID: 28591758
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Viral encephalitis after haplo-identical hematopoietic stem cell transplantation: Causative viral spectrum, characteristics, and risk factors.
    Zhang XH; Zhang JM; Han W; Chen H; Chen YH; Wang FR; Wang JZ; Zhang YY; Mo XD; Chen Y; Wang Y; Chang YJ; Xu LP; Liu KY; Huang XJ
    Eur J Haematol; 2017 May; 98(5):450-458. PubMed ID: 28129450
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Viral reactivations following hematopoietic stem cell transplantation in pediatric patients - A single center 11-year analysis.
    Düver F; Weißbrich B; Eyrich M; Wölfl M; Schlegel PG; Wiegering V
    PLoS One; 2020; 15(2):e0228451. PubMed ID: 32017805
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of in vivo T cell depletion with alemtuzumab on reduced-intensity allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia.
    Delgado J; Pillai S; Benjamin R; Caballero D; Martino R; Nathwani A; Lovell R; Thomson K; Perez-Simon JA; Sureda A; Kottaridis P; Vazquez L; Peggs K; Sierra J; Milligan D; Mackinnon S
    Biol Blood Marrow Transplant; 2008 Nov; 14(11):1288-97. PubMed ID: 18940684
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders.
    Pérez-Simón JA; Kottaridis PD; Martino R; Craddock C; Caballero D; Chopra R; García-Conde J; Milligan DW; Schey S; Urbano-Ispizua A; Parker A; Leon A; Yong K; Sureda A; Hunter A; Sierra J; Goldstone AH; Linch DC; San Miguel JF; Mackinnon S;
    Blood; 2002 Nov; 100(9):3121-7. PubMed ID: 12384408
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HLA-mismatched unrelated donors are a viable alternate graft source for allogeneic transplantation following alemtuzumab-based reduced-intensity conditioning.
    Mead AJ; Thomson KJ; Morris EC; Mohamedbhai S; Denovan S; Orti G; Fielding AK; Kottaridis PD; Hough R; Chakraverty R; Linch DC; Mackinnon S; Peggs KS
    Blood; 2010 Jun; 115(25):5147-53. PubMed ID: 20371745
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of alemtuzumab pharmacokinetics on T-cell dynamics, graft-versus-host disease and viral reactivation in patients receiving allogeneic stem cell transplantation with an alemtuzumab-based T-cell-depleted graft.
    Loeff FC; van Egmond EHM; Moes DJAR; Wijnands C; Von Dem Borne PA; Veelken H; Falkenburg JHF; Jedema I; Halkes CJM
    Transpl Immunol; 2019 Dec; 57():101209. PubMed ID: 31207283
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of alemtuzumab used for in vivo and in vitro T-cell depletion in allogeneic transplantations: relevance for early adoptive immunotherapy and infectious complications.
    Morris EC; Rebello P; Thomson KJ; Peggs KS; Kyriakou C; Goldstone AH; Mackinnon S; Hale G
    Blood; 2003 Jul; 102(1):404-6. PubMed ID: 12623851
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sequential Onset of Varicella-Zoster Virus Encephalomeningitis and Progressive Multifocal Leukoencephalopathy in an Allogeneic Hematopoietic Stem Cell Transplant Recipient.
    Yamashita Y; Kusakabe S; Toda J; Ohshima K; Masaie H; Yagi T; Yoshida H; Ishikawa J
    Exp Clin Transplant; 2018 Oct; 16(5):628-630. PubMed ID: 27938314
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human herpesvirus-6B infection in pediatric allogenic hematopoietic stem cell transplant patients: Risk factors and encephalitis.
    Miura H; Kawamura Y; Hattori F; Tanaka M; Kudo K; Ihira M; Yatsuya H; Takahashi Y; Kojima S; Sakaguchi H; Yoshida N; Hama A; Yoshikawa T
    Transpl Infect Dis; 2020 Feb; 22(1):e13203. PubMed ID: 31650671
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD52 antibodies for prevention of graft-versus-host disease and graft rejection following transplantation of allogeneic peripheral blood stem cells.
    Hale G; Jacobs P; Wood L; Fibbe WE; Barge R; Novitzky N; Toit C; Abrahams L; Thomas V; Bunjes D; Duncker C; Wiesneth M; Selleslag D; Hidajat M; Starobinski M; Bird P; Waldmann H
    Bone Marrow Transplant; 2000 Jul; 26(1):69-76. PubMed ID: 10918407
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Large-scale multiplex polymerase chain reaction assay for diagnosis of viral reactivations after allogeneic hematopoietic stem cell transplantation.
    Inazawa N; Hori T; Hatakeyama N; Yamamoto M; Yoto Y; Nojima M; Suzuki N; Shimizu N; Tsutsumi H
    J Med Virol; 2015 Aug; 87(8):1427-35. PubMed ID: 25946433
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Herpesvirus-associated central nervous system diseases after allogeneic hematopoietic stem cell transplantation.
    Wu M; Huang F; Jiang X; Fan Z; Zhou H; Liu C; Jiang Q; Zhang Y; Zhao K; Xuan L; Zhai X; Zhang F; Yin C; Sun J; Feng R; Liu Q
    PLoS One; 2013; 8(10):e77805. PubMed ID: 24124621
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Addition of varicella zoster virus-specific T cells to cytomegalovirus, Epstein-Barr virus and adenovirus tri-specific T cells as adoptive immunotherapy in patients undergoing allogeneic hematopoietic stem cell transplantation.
    Ma CK; Blyth E; Clancy L; Simms R; Burgess J; Brown R; Deo S; Micklethwaite KP; Gottlieb DJ
    Cytotherapy; 2015 Oct; 17(10):1406-20. PubMed ID: 26349000
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BEAM-alemtuzumab reduced-intensity allogeneic stem cell transplantation for lymphoproliferative diseases: GVHD, toxicity, and survival in 65 patients.
    Faulkner RD; Craddock C; Byrne JL; Mahendra P; Haynes AP; Prentice HG; Potter M; Pagliuca A; Ho A; Devereux S; McQuaker G; Mufti G; Yin JL; Russell NH
    Blood; 2004 Jan; 103(2):428-34. PubMed ID: 12969983
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.